Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Interest & Investment Income of -$640000.0 for Q1 2026, down 592.31% on a QoQ basis from $130000.0 in Q4 2025, and down 31900.0% year-over-year from N/an in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Interest & Investment Income history runs 10 years deep, the most recent figure standing at -$640000.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 31900.0% year-over-year to -$640000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$500000.0 (down 346.43% YoY) and the FY2025 annual result came in at $138000.0, up 181.66% from the prior year.
- Interest & Investment Income was -$640000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, down from $130000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $130000.0 in Q4 2025 and bottomed at -$640000.0 in Q1 2026.
- A 5-year average of -$35235.3 and a median of -$2000.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 735.71% — and 2026, when it sank 31900.0%.
- Kiniksa Pharmaceuticals International's Interest & Investment Income stood at $114000.0 in 2022, then sank by 93.86% to $7000.0 in 2023, then sank by 1842.86% to -$122000.0 in 2024, then soared by 206.56% to $130000.0 in 2025, then slumped by 592.31% to -$640000.0 in 2026.
- Business Quant data shows KNSA's Interest & Investment Income at -$640000.0 in Q1 2026, $130000.0 in Q4 2025, and -$102000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 4.91 Bn | 4.45 Bn | 193.47 Mn | -640,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -640,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -102,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | -122,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | -77,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | -14,000.00 |
| Jun 30, 2023 | -42,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 114,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | -37,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Sep 30, 2021 | -72,000.00 |
| Jun 30, 2021 | 48,000.00 |